Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

A Longitudinal Assessment of Fingolimod on White Brain Matter and Disease Disability in Relapsing Remitting Multiple Sclerosis
Multiple Sclerosis
P2 - Poster Session 2 (8:00 AM-9:00 AM)
9-021
To assess the effect of Fingolimod (FTY) on Corpus Callosum Area (CCA), Diffusion Tensor Imaging (DTI), and disease disability in Relapsing Remitting Multiple Sclerosis (RRMS) patients.
The safety and efficacy of FTY has been well established in RRMS patients. It has been shown that there is a faster progression of brain atrophy associated with RRMS. It is also well known that disability increases over the course of the disease and there is a possible association between disability and CCA.
40 RRMS patients on FTY (mean age±SD; 42.0±9.6y, mean disease duration±SD; 9.3±7.0y) were included in this longitudinal, retrospective, single center analysis. MRI scans and disease progression were measured at three time points (baseline, year 1, and year 2). All MRI images were obtained on a 3.0 Tesla magnet and processed using Jim (v6). DTI measures include the following: Fractional Ansiotropy (FA), Apparent Diffusion Coefficient (ADC), Axial Diffusivity (AD), and Radial Diffusivity (RD). Disease disability was measured with the Expanded Disability Status Scale (EDSS). A general linear model with multivariate analysis (MANOVA) was used to analyze our data (SPSS vs 25). Age and disease duration were included as covariates for our analysis.
Our results revealed no significant changes on CCA over the course of 2 years of FTY treatment (p=0.968). Similarly, there were no significant effects seen on EDSS score for RRMS patients treated with FTY for 2 years (p=0.932). Over the 2 year course of treatment of FTY, there was no significant changes on FA (p=0.580).
Our data suggests that Fingolimod may have a neuroprotective role on CCA and DTI measures in RRMS. FTY may also have a protective factor on disease disability as measured by the EDSS. Further longitudinal studies with larger samples should be conducted to confirm our findings.
Authors/Disclosures
Melody Gilroy, BS
PRESENTER 		Ms. Gilroy has nothing to disclose.
No disclosure on file
Fen Bao Fen Bao has nothing to disclose.
Carla E. Santiago-Martinez (Wayne State University) Ms. Santiago-Martinez has nothing to disclose.
Evanthia Bernitsas, MD, FÂ鶹´«Ã½Ó³»­ (Wayne State School of Medicine) Dr. Bernitsas has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amgen. Dr. Bernitsas has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Vanda. The institution of Dr. Bernitsas has received research support from Roche/Genentech.